ChromaDex’s Niagen IV Now Available at 200+ Restore Hyper Wellness Clinics
The treatment option, now available at Restore Hyper Wellness clinics nationwide, offers a streamlined approach to NAD+ support, aiming to improve cellular health
National wellness clinic chain Restore Hyper Wellness has introduced ChromaDex Corp.’s pharmaceutical-grade Niagen IV therapy at more than 200 locations. This expanded rollout makes the intravenous NAD+ treatment more accessible across the U.S., offering clients a new option for cellular support as they age.
Niagen, a form of nicotinamide riboside developed by ChromaDex, serves as a precursor to NAD+, a coenzyme essential to energy production and metabolic processes in the body. Studies indicate that NAD+ levels decline with age and certain lifestyle factors, including stress, diet, and physical inactivity, which has led to increasing interest in therapies that aim to boost these levels.
ChromaDex reports that Niagen IV, in pilot studies, showed a 20% increase in blood NAD+ levels within three hours of infusion, with a 75% shorter infusion time than traditional NAD+ IV treatments. According to Rob Fried, ChromaDex CEO, Niagen IV was developed as an efficient alternative to NAD+ IV therapy.
“Niagen IV is a superior solution to traditional NAD+ IV,” said Rob Fried, CEO of ChromaDex. “We are pleased that reliably science-based Restore Hyper Wellness recognizes these advantages and is offering Niagen IV nationwide.”
Restore Hyper Wellness, which offers a range of health-focused treatments, aims to provide clients with new tools for wellness support. Restore’s extensive network of clinics offers clients a holistic experience designed to address their wellness goals and optimize physical health.
“We’ve seen firsthand how Niagen IV elevates the wellness experience for our clients, delivering enhanced cellular support compared to NAD+ IV,” said Dr. Rachele Pojednic, director of scientific research & education at Restore Hyper Wellness. “Pharmaceutical-grade Niagen provides a cutting-edge option that reflects our commitment to impactful, science-driven care.”
Niagen IV is produced at Wells Pharma, an FDA-registered 503B outsourcing facility, and distributed to clinics under medical supervision. ChromaDex continues to research and develop applications for its NAD+ precursor products as part of its focus on healthy aging.